PascaZeneca: Soriot shapes a company
This article was originally published in Scrip
AstraZeneca is being Pascalized. For an AstraZeneca CEO, Pascal Soriot has been remarkably candid with investors and analysts in the half year since he arrived. Gone is the sense of a company cringeing at the thought of quarterly figures and an ill-timed deflective managerial shake-up. Now it’s Pascal-time: a new, fragrant, open beginning. Thought and action; transparency in both.